Decrease in existing BODY WEIGHT.
| Excerpt | Reference |
|---|
| "Although weight loss is occasionally reversible with treatment of underlying infections and/or easily identifiable and reversible causes, the majority of patients are not this fortunate." | ( Craig, R; Roth, EL; Von Roenn, JH, 1992) |
| "This average weight loss is in the range typically found for similar programmes." | ( Smith, RB; Welch, G, 1992) |
| "The weight loss is exacerbated by Salmonella infection with mice receiving bryostatin 1 and S." | ( Adler, V; Benjamin, WH; Briles, DE; Hall, P; Kraft, AS; Pettit, GR, 1992) |
| "The resultant weight loss is variable and there appears to be no way of predicting good responders, nor is there evidence that additional weight loss attributable to drug therapy is sustained once treatment is discontinued, although nonpharmacological strategies for preventing weight regain are worthy of exploration." | ( Hodge, J; Munro, JF; Scott, C, 1992) |
| "We conclude that weight loss is beneficial in all obese hyperandrogenic women regardless of the presence of polycystic ovaries, the degree of hyperandrogenism, and the degree and distribution of obesity." | ( Antenucci, D; Balestra, V; Barbara, L; Casimirri, F; Fabbri, R; Melchionda, N; Paradisi, R; Pasquali, R; Venturoli, S, 1989) |
| "Weight loss is known to alter food intake and drug self-administration, but the neural basis of this is unknown." | ( Creese, I; Hoebel, BG; Pothos, EN, 1995) |
| "Hypermetabolism and weight loss are related to the presence of a systemic inflammatory response as reflected by enhanced levels of inflammatory mediators and acute phase proteins in patients with primary non-small-cell lung cancer." | ( Buurman, WA; Dentener, MA; Schols, AM; Staal-van den Brekel, AJ; Wouters, EF, 1995) |
| "Weight loss is a part of any competitive sport which matches participants of equal weight or sports where participating at lower weights or with a thinner body habitus is considered an advantage." | ( Almquist, J; Conkwright, D; Cutter, D; Gregory, D; Perriello, VA; Pitrezzi, MJ; Roemmich, J; Snyders, G, 1995) |
| "Severe weight loss is a common manifestation of advanced infection with the human immunodeficiency virus." | ( Landman, D; Sarai, A; Sathe, SS, 1994) |
| "Weight loss is a well recognised feature of patients with emphysematous chronic obstructive pulmonary disease (COPD)." | ( Banham, SW; Carter, R; Lean, ME; Sridhar, MK, 1994) |
| "Since weight loss is commonly prescribed during the clinical management of hypertensives with concomitant hypercholesterolemia, consideration should be given to the attenuating effect of chlorthalidone on cholesterol reduction in the management of these patients." | ( Belcher, J; Bradley, K; Elmer, P; Flack, JM; Grimm, R; Miller, P, 1993) |
| "We conclude that weight loss is enhanced by OROS-PPA, but this change was not explained by changes in 24-h EE or 24-h RQ." | ( Alger, S; Boyce, VL; Ferraro, RT; Fontvieille, AM; Larson, K; Ravussin, E; Rising, R; Seagle, H, 1993) |
| "Weight loss is the main symptom of so-called tumor cachexia." | ( Denz, H; Fuchs, D; Herrmann, R; Huber, P; Orth, B; Wachter, H; Weiss, G, 1993) |
| "The early stages of weight loss are associated with a reduction in blood pressure, and the mechanisms mediating this reduction remain unclear." | ( Hmeidan, A; Jacobs, DB; Niyogi, T; Simpson, L; Sowers, JR; Standley, PR, 1993) |
| "Weight loss is therefore associated with a reduction in aspects of the acute phase response, but this is due to impaired effectiveness rather than reduced magnitude of the cytokine response." | ( Curtis, GE; Formela, L; McAtear, CA; Shenkin, A; Walsh, A, 1995) |
| "Weight loss is commonly associated with increased morbidity and mortality in individuals with human immunodeficiency virus (HIV) infection." | ( Blackman, MR; Dobs, AS; Few, WL; Graham, NM; Harman, SM; Hoover, DR, 1996) |
| "Weight loss is not required to increase HDL-C with exercise training in overweight men, but without weight loss, even prolonged exercise training produces only modest changes in HDL-C concentrations." | ( Bausserman, L; Flynn, MM; Herbert, PN; Saritelli, A; Spannaus-Martin, D; Thompson, PD; Yurgalevitch, SM; Zmuda, JM, 1997) |
| "Weight loss is a frequently occurring problem in patients with lung cancer due to an increased resting energy expenditure (REE) and a decreased energy intake." | ( Buurman, WA; Dentener, MA; Schols, AM; Staal-van den Brekel, AJ; ten Velde, GP; Wouters, EF, 1997) |
| "In many cases, the weight loss is non-responsive to long term antibiotic therapy." | ( Baarsch, MJ; Harding, JC; Murtaugh, MP, 1997) |
| "Major weight loss is associated with sustained and marked improvements in blood lipids and hemostatic profile, irrespective of the tested slimming and maintenance regimens." | ( Astrup, A; Marckmann, P; Toubro, S, 1998) |
| "Sibutramine-induced weight loss is associated with beneficial changes in obesity-related risk factors, such as serum lipids, uric acid levels, and glycaemic control (in patients with type 2 diabetes)." | ( De Leeuw, IH; Van Gaal, LF; Wauters, MA, 1998) |
| "Unexplained weight loss is common in patients with chronic obstructive pulmonary disease (COPD)." | ( Abe, S; Hino, T; Kato, S; Nakamura, H; Saito, H; Takabatake, N; Tomoike, H; Yuki, H, 1999) |
| "The dose of PPA for weight loss is 75 mg/day." | ( Greenway, F; Herber, D; Morales, S; Raum, W, 1999) |
| "Weight loss is a strong predictor of morbidity and mortality in human immunodeficiency virus (HIV)-infected patients." | ( Anderson, R; Cofrancesco, J; Danoff, A; Dobs, AS; Feinberg, J; Hamilton, CD; Nolten, WE; Rhame, F; Seekins, D; Yangco, B, 1999) |
| "Unintentional weight loss is a diagnostic dilemma with diverse diagnostic possibilities for physicians." | ( Lee, LT; Lee, YC; Leung, KK; Li, CM; Lin, HW, 1999) |
| "Obesity and weight loss are important risk factors for gallstone development." | ( Manríquez, M; Severín, C; Valdivieso, V; Zapata, R, 2000) |
| "Weight loss is theoretically simple: decrease energy intake, increase energy use, or both." | ( Glasziou, P; Pirozzo, S, 2000) |
| "A diet-induced weight loss is accompanied by a significant decrease in bone mineral density (BMD) and total body bone mineral (TBBM), but the underlying mechanisms are not clarified." | ( Jensen, LB; Kollerup, G; Quaade, F; Sørensen, OH, 2001) |
| "Pathological weight loss is a feature of many diseases and contributes to mortality and morbidity." | ( Berkowitz, DE; Breslow, MJ; Brown, DR, 2001) |
| "Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide." | ( Coblyn, JS; Helfgott, S; Shadick, N, 2001) |
| "Long-term weight loss is mandatory to lengthen the survival; therefore, the lack of compliance in voluntary food restriction requires a surgical malabsorptive approach." | ( Adami, GF; Camerini, G; Marinari, GM; Marini, P; Murelli, F; Novelli, GB; Papadia, F; Scopinaro, N, 2001) |
| "Moderate weight loss is associated with noticeably improved HRQOL." | ( Kolotkin, RL; Mendel, CM; Nguyen, MH; Samsa, GP; Williams, GR, 2001) |
| "Weight loss is typically found during severe infections, e." | ( Hultgren, OH; Tarkowski, A, 2001) |
| "Anorexia and weight loss are frequent complications of acute and chronic infections and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination." | ( Burney, MW; Johnson, PM; Muglia, LJ; Vogt, SK, 2002) |
| "When weight loss is induced with a very low calorie diet (VLCDL), patients randomized to the sibutramine treatment continued to lose weight over a 1 year period, reaching 15% below baseline, whereas the placebo-treated patients regained some weight." | ( Carruba, MO; Nisoli, E, 2000) |
| "Weight loss is common in patients with neurodevelopmental disabilities who receive topiramate." | ( Brown, RO; Dickerson, RN; Hanna, DL; Orr, CD; Williams, JE, 2002) |
| "Weight loss is the most effective means of reducing lipid and lipoprotein risk factors in obese women." | ( Brock, DW; Butterworth, D; Nieman, CC; Nieman, DC; Utter, AC, 2002) |
| "Weight loss is a common complication of COPD, associated with negative outcomes." | ( DeGuzman, B; Kramer, T; Yeh, SS, 2002) |
| "Improvement with weight loss is related to the decrease in fasting glucose, improvement in insulin sensitivity, and the extent of weight lost." | ( Dixon, JB; O'Brien, PE, 2002) |
| "Orlistat weight loss is associated with improvements in cardiovascular co-morbidities, and hence cardiovascular risk." | ( Broom, I; Myers, N; Stott, P; Wilding, J, 2002) |
| "Substantial weight loss is accompanied by a marked attenuation of insulin resistance and related metabolic syndrome and, concomitantly, by a remarkable regression of liver steatosis in most patients, although increased inflammation may be detected in some subjects." | ( Luyckx, FH; Scheen, AJ, 2002) |
| "Weight loss is a common problem in patients with Alzheimer's disease (AD) and this might be associated with an increased risk for mortality." | ( Arai, H; Higuchi, M; Hu, X; Itoh, M; Maruyama, M; Okamura, N; Sasaki, H; Yamaguchi, K, 2002) |
| "Weight loss is associated with an increase in fasting plasma ghrelin." | ( Geloneze, B; Geloneze, SR; Pareja, JC; Pilla, VF; Repetto, EM; Tambascia, MA, 2003) |
| "Sustained weight loss is a safe method to ameliorate diastolic nighttime BP drop and sympathetic overactivity, which may reduce the cardiovascular risk in obese women." | ( Carusone, C; Esposito, K; Giugliano, D; Giugliano, G; Gualdiero, P; Marfella, R; Nicoletti, G; Pontillo, A, 2003) |
| "Moderate weight loss is recommended for overweight and obese patients with type 2 diabetes, and conjunctive use of weight loss medication has been advocated." | ( Harper, P; Kalhan, S; Kelley, DE; Kuller, LH; Mancino, J; McKolanis, TM, 2004) |
| "This weight loss is associated with improvements in blood pressure, insulin sensitivity, and dyslipidemia." | ( Aronne, LJ; Thearle, M, 2003) |
| "Weight loss is associated with an increased risk of symptomatic gallstones." | ( Craanen, ME; Mijnhout, GS; Smulders, YM, 2004) |
| "Weight loss is known to impact survival among patients infected with human immunodeficiency virus (HIV) even in the era of highly active antiretroviral therapy (HAART)." | ( Albrecht, M; Chang, H; Forfia, J; Gerrior, J; Miller, L; Mwamburi, DM; Saboori, S; Scully, E; Wanke, CA; Wilson, IB, 2004) |
| "The primary goal of weight loss is to prevent or reduce obesity-associated morbidity and mortality by improving cardiovascular and metabolic risk factors." | ( Arterburn, DE; Crane, PK; Veenstra, DL, 2004) |
| "RYGB-induced weight loss is associated with changes in gene profile expressions that could influence metabolic changes, contributing to weight loss." | ( Chen, C; Das, U; Inui, A; Meguid, MM; Middleton, F; Quinn, R; Ramos, EJ; Romanova, I; Xu, Y, 2004) |
| "Advice about weight loss is critical in modern management of PCOS and infertility." | ( Homburg, R, 2004) |
| "The incidence of weight loss is very similar between donepezil- and placebo-treated patients." | ( Ham, RJ; Jackson, S; Wilkinson, D, 2004) |
| "Diarrhoea and weight loss are frequently reported adverse events in rheumatoid arthritis (RA) patients receiving the disease-modifying antirheumatic drug (DMARD) leflunomide." | ( Vandooren, AK; Verschueren, P; Westhovens, R, 2005) |
| "The magnitude of weight loss is modest, however, and the long-term health benefits remain unclear." | ( Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2005) |
| "Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses." | ( Fleming, R; Harborne, LR; Norman, JE; Sattar, N, 2005) |
| "Weight loss is desirable in obese patients prior to hip replacement but poor mobility secondary to hip dysfunction may limit attempts at weight reduction because of reduced exercise tolerance." | ( Aderinto, J; Brenkel, IJ; Chan, P, 2005) |
| "Body weight loss is a common but one of the most serious sequelae after gastrectomy." | ( Doki, Y; Hosoda, H; Imaoka, S; Ishikawa, O; Kangawa, K; Miyashiro, I; Murata, K; Nakajima, H; Ohigashi, H; Sasaki, Y; Sasakuma, F; Takachi, K, 2006) |
| "Weight loss is often refractory to the nutritional support." | ( Haluzík, M; Novák, F; Pazdrová, G; Petruzelka, L; Svobodník, A; Zemanová, M, 2005) |
| "Early weight loss is generally considered to predict long-term weight outcome in obese patients, and this is reflected in prescribing guidelines for antiobesity drugs." | ( Finer, N; Hewkin, AC; Renz, CL; Ryan, DH, 2006) |
| "Weight regain after weight loss is the most significant impediment to long-term weight reduction." | ( Fleming-Elder, BK; Higgins, JA; Hill, JO; Jackman, MR; Johnson, GC; MacLean, PS; Melanson, EL; Wyatt, HR, 2006) |
| "Body weight loss is observed commonly after esophagectomy with gastric tube reconstruction in thoracic esophageal cancer patients." | ( Doki, Y; Hosoda, H; Imaoka, S; Ishikawa, O; Kangawa, K; Miyashiro, I; Motoori, M; Nakajima, H; Ohigashi, H; Sasaki, Y; Sasakuma, F; Takachi, K, 2006) |
| "Weight loss is associated with different changes, depending on the FABP2 genotype." | ( Aller, R; Conde, R; de Luis, DA; Izaola, O; Sagrado, MG, 2006) |
| "Body weight loss is negatively associated with subsequent reproductive performance." | ( Kemp, B; van den Brand, H, 2006) |
| "Surgically induced weight loss is capable of reversing low-grade inflammation, at least partially." | ( Calvani, M; Castagneto, M; Equitani, F; Fernandez-Real, JM; Manco, M; Mingrone, G; Nanni, G; Ricart, W; Tondolo, V; Valera Mora, ME; Vendrell, J, 2007) |
| "The incidence of weight loss is greater in dually treated patients with HIV/HCV than in treated HCV- or HIV-monoinfected patients." | ( Frank, I; Gross, R; Kostman, JR; Lo Re, V; Mounzer, K; Putt, M; Reddy, KR; Rennert, H; Stieritz, DD; Strom, BL; Zemel, BS, 2007) |
| "For women in whom weight loss is not possible, or for lean women with PCOS, clomiphene citrate is an effective first-line method of ovulation induction." | ( Guzick, DS, 2007) |
| "Anorexia and weight loss are part of the wasting syndrome of late-stage cancer, are a major cause of morbidity and mortality in cancer, and are thought to be cytokine mediated." | ( Apple, FS; Baldock, PA; Bauskin, AR; Breit, SN; Brown, DA; Corey, E; During, MJ; Enriquez, RF; Fairlie, WD; Herzog, H; Hunter, M; Jiang, L; Johnen, H; Junankar, S; Kuffner, T; Lee, NJ; Lin, EJ; Lin, S; Murakami, MM; Pankhurst, G; Sainsbury, A; Tsai, VW; Wang, C; Wu, L, 2007) |
| "--Weight loss is an important part of the treatment of obese, hirsute women with PCOS." | ( Pijl, H; van Zuuren, EJ, 2007) |
| "When substantial weight loss is required, meal replacements allow a large reduction in energy consumption whilst maintaining micronutrient intake." | ( Gagliardi, L; Wittert, G, 2007) |
| "Weight loss is a central component of frailty." | ( Morley, JE, 2007) |
| "Weight loss is reported by more than 20% of hepatitis C virus (HCV)-monoinfected patients treated with the peg-interferon (peg-IFN) and ribavirin combination." | ( Bani-Sadr, F; Bensalem, M; Cacoub, P; Carrat, F; Lapidus, N; Melchior, JC; Perronne, C; Pol, S; Ravaux, I; Rosa, I, 2008) |
| "Weight loss is common in patients with chronic obstructive pulmonary disease (COPD)." | ( Chung, JH; Lee, KH; Shin, KC, 2007) |
| "The weight loss is modest, approximately 5 %, and the patients regain their baseline weight within 9 months after withdrawal." | ( Aronsen, L, 2008) |
| "Weight loss is recommended in all major guidelines for antihypertensive therapy." | ( Gratzer, TW; Horvath, K; Jeitler, K; Siebenhofer, A; Siering, U; Skipka, G; Stich, AK, 2008) |
| "Maintenance of weight loss is often unsuccessful because of metabolic adaptations that conserve energy." | ( Ahima, RS, 2008) |
| "Weight loss is an independent risk factor for mortality in HIV but the role of drug use in HIV-related weight loss is not well described." | ( Forrester, JE; Skinner, S; Terrin, N; Tucker, KL, 2008) |
| "Although voluntary weight loss is often not successful to reverse the disease process, various surgical procedures have proven effective in reducing overweight situations and liver steatosis." | ( Moschen, AR; Tilg, H, 2008) |
| "Similar weight loss is associated with different changes, depending on the FABP genotype with both diets." | ( Aller, R; Conde, R; de Luis, DA; Izaola, O; Sagrado, MG, 2008) |
| "Weight loss is associated with reduction of blood pressure and of PRA and aldosterone levels in obese hypertensive subjects." | ( Dall'Asta, C; Folli, F; Manunta, P; Marchi, M; Paganelli, M; Pizzocri, P; Pontiroli, AE; Vedani, P, 2009) |
| "Weight loss is considered to be the initial step which helps to prevent or to control the clinical consequences of obesity." | ( Idelevich, E; Kirch, W; Schindler, C, 2009) |
| "Weight loss is a common problem in Parkinson's disease (PD), but the causative mechanisms behind this weight loss are unclear." | ( Granérus, AK; Lorefält, B; Toss, G, 2009) |
| "This suggests that weight loss is a more potent intervention than strength training in improving balance recovery using an ankle strategy." | ( Madigan, ML; Matrangola, SL, 2009) |
| "Anorexia and weight loss are associated with increased mortality in cachectic patients." | ( Morley, JE, 2009) |
| "Substantial weight loss is necessary to increase RCT." | ( Kovář, J; Králová Lesná, I; Poledne, R; Suchánek, P, 2009) |
| "Weight loss is known to improve both cardiovascular risk and OSA severity." | ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "Weight loss is the best treatment option, which can be a challenging task for patients to achieve and maintain." | ( Brown, A; Desai, M; Taneja, D; Tannock, LR, 2010) |
| "Weight loss is thought to be a key to improving all aspects of metabolic syndrome." | ( Chen, HJ; Foreyt, JP; Haddock, CK; Holt, RR; Kazaks, AG; Keen, CL; Khoo, CS; Poston, WS; Reeves, RS; Shenoy, SF; Winters, BL, 2010) |
| "Progressive weight loss is a hallmark feature of Huntington's disease, yet we found that the ketogenic diet-which generally causes weight loss in normal animals-delayed the reduction in body weight of the transgenic mice." | ( Geiger, JD; Kawamura, M; Masino, SA; Ross, JL; Ruiz, TL; Ruskin, DN, 2011) |
| "Weight loss is effective in decreasing liver fat in subjects who are homozygous for the rs738409 PNPLA3 G or C allele." | ( Ferrannini, E; Gastaldelli, A; Hakkarainen, A; Kotronen, A; Lundbom, J; Lundbom, N; Olkkonen, VM; Orho-Melander, M; Perttilä, J; Rissanen, A; Sevastianova, K; Suojanen, L; Yki-Järvinen, H, 2011) |
| "Weight loss is the most important non-neurological complication of Huntington's disease (HD)." | ( Aziz, NA; Bates, GP; Björkqvist, M; Brundin, P; Maat-Schieman, ML; Roos, RA; van der Burg, JM; Wierup, N; Winqvist, A, 2011) |
| "Weight loss is comparable to younger patients and enough to resolve the comorbidities in most of the patients." | ( Jaser, N; Juuti, A; Leivonen, MK; Mustonen, H, 2011) |
| "This weight loss is accompanied by changes in adipose tissue (AT) distribution." | ( Beaver, JD; Bell, JD; Berk, ES; Delafont, B; Frost, G; Gambarota, G; Makwana, A; Matthews, PM; Mishra, RG; Newbould, R; Rao, AW; Schwartz, SM; Thomas, EL, 2011) |
| "In conclusion, weight loss is effective in treating obese children with SDB." | ( Aerts, P; De Backer, WA; Debode, P; Desager, KN; Franckx, H; Ramet, J; Van Gaal, LF; Van Hoorenbeeck, K; Verhulst, SL; Wouters, K, 2012) |
| "Long-term weight loss is related to a characteristic response suggestive of altered cholesterol and apolipoprotein metabolism." | ( Blüher, M; Ceglarek, U; Fiedler, GM; Gepner, Y; Golan, R; Helmschrodt, C; Henkin, Y; Leichtle, AB; Schwarzfuchs, D; Shai, I; Stampfer, MJ; Stumvoll, M; Thiery, J, 2011) |
| "A substantial weight loss is achieved in the months following surgery, which is likely to reduce psoriasis symptoms and risk of comorbidities." | ( Faurschou, A; Knop, FK; Skov, L; Vilsbøll, T; Zachariae, C, 2011) |
| "Weight loss is often recommended to reverse these metabolic alterations and the use of a high-protein (HP), low-carbohydrate diet is encouraged." | ( Hargrave, SL; Honors, MA; Kinzig, KP, 2012) |
| "Although weight loss is frequently initiated successfully, most patients regain substantial amounts of weight within the first year after completing a weight loss programme." | ( Gage, D, 2012) |
| "Weight loss is related to adherence to metformin and is durable for at least 10 years of treatment." | ( , 2012) |
| "Weight loss is a characteristic finding of patients with Alzheimer's disease (AD)." | ( Kyriazopoulou, V; Metallinos, IC; Psyrogiannis, A; Theodoropoulou, A; Vagenakis, GA, 2012) |
| "Weight loss is often difficult to achieve in individuals with type 2 diabetes and anti-obesity drugs are often advocated to support dietary intervention." | ( Bunce, S; Heppenstall, C; Smith, JC, 2012) |
| "Although weight loss is similar (30 ± 19 kg MO vs 28 ± 12 kg SO, P = ." | ( Browne, A; Fantuzzi, G; Guzman, G; Henriques, S; Holterman, AX; Holterman, M, 2012) |
| "As weight loss is seldom maintained in a single effort, weight cycling is a common occurrence." | ( Berryman, DE; Funk, K; Jara, A; Kopchick, JJ; List, EO; Wright-Piekarski, J, 2013) |
| "Body weight loss is a common outcome in patients with gastric cancer who have undergone gastrectomy." | ( Aoyama, T; Cho, H; Hayashi, T; Kitani, Y; Masuda, M; Ogata, T; Oshima, T; Ozawa, Y; Rino, Y; Shirai, J; Tsuburaya, A; Wada, H; Yoshikawa, T; Yukawa, N, 2012) |
| "Weight loss is therefore considered the first line treatment in overweight women with PCOS." | ( Glintborg, D; Haugen, AG; Ravn, P, 2013) |
| "Weight loss is most effectively achieved through a 12-1500 kcal/day diet, which results in a clinically relevant weight loss." | ( Glintborg, D; Haugen, AG; Ravn, P, 2013) |
| "Diet-induced weight loss is accompanied by compensatory changes, which increase appetite and encourage weight regain." | ( Delbridge, E; Kriketos, A; Prendergast, LA; Proietto, J; Purcell, K; Shulkes, A; Sumithran, P, 2013) |
| "Weight loss is an effective measure for alleviating many of these metabolic abnormalities." | ( Atkinson, RL; Cani, PD; Casteilla, L; Clement, K; Dhurandhar, NV; Gerard, P; Geurts, L; Nam, JH; Nieuwdorp, M; Sørensen, TI; Trovato, G; Vidal-Puig, A; Vijay-Kumar, M, 2013) |
| "Weight loss is one of the side effects of interferon therapy." | ( Ahmed, Wu; Alam, SE; Arif, A; Sajjad, SF; Waquar, J, 2012) |
| "Weight loss is associated with down-regulation of sympathetic nervous activity but no overall alteration in disposition indices." | ( Dawood, T; Dixon, JB; Eikelis, N; Esler, MD; Grima, MT; Lambert, EA; Lambert, GW; Masuo, K; Nestel, PJ; Paul, E; Richards, K; Sari, CI; Schlaich, MP; Straznicky, NE, 2014) |
| "Weight loss is similar in MGB and LSG in the first years, but lesser %EWL with LSG at 5 years (68 % in MGB vs 51 % in LSG)." | ( Kular, KS; Manchanda, N; Rutledge, R, 2014) |
| "Weight loss is the result of a sustained negative energy balance, which is typically achieved by decreasing food intake and/or increasing physical activity." | ( Batterham, RL; Deighton, K; Stensel, DJ, 2014) |
| "Weight loss is a prominent early feature of Alzheimer's disease (AD) that often precedes the cognitive decline and clinical diagnosis." | ( Dyke, JP; Iadecola, C; Ishii, M; Racchumi, G; Wang, G, 2014) |
| "Weight loss is not a benign phenomenon." | ( Sharma, JC; Vassallo, M, 2014) |
| "Body weight loss is prevented also in mice bearing the C26 colon carcinoma, classically reported to induce cachexia in immunocompetent mice." | ( Bani, MR; Bassi, A; Bisighini, C; Damia, G; Fiordaliso, F; Ghilardi, C; Giavazzi, R; Moschetta, M; Piccirillo, R; Pretto, F; Rovida, A; Scarlato, V; Talamini, L, 2015) |
| "A threshold of weight loss is necessary to improve male reproductive function by reversing male hypogonadism, manifested as increased testosterone levels." | ( Cooney, RN; Kesner, JS; Krieg, EF; Kunselman, AR; Legro, RS; Meadows, JW; Rogers, AM, 2015) |
| "As weight loss is known to reduce both HbA1c and SBP, these analyses were performed to evaluate the contribution of weight loss resulting from treatment with canagliflozin to HbA1c and SBP reductions in patients with type 2 diabetes." | ( Blonde, L; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Polidori, D; Stenlöf, K; Sullivan, D; Usiskin, K; Wilding, JP; Xie, J, 2015) |
| "Weight loss is commonly seen after stroke." | ( Cai, L; Ding, Y; Du, H; Gao, Z; Geng, X; Hussain, M; Ji, X; Liu, S; Liu, Z, 2015) |
| "While intentional weight loss is thought to improve prognosis, its impact on these adipokines is unclear." | ( Lakoski, SG; Matthews, SB; McGinley, JN; Paul, D; Playdon, MC; Sedlacek, SM; Thompson, HJ; Wolfe, P, 2015) |
| "Weight loss is associated with improved quality of life in some, but not all, weight loss trials." | ( Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL, 2015) |
| "Whilst weight loss is known to enhance insulin clearance, there is a paucity of data concerning the underlying mechanisms." | ( Dixon, JB; Eikelis, N; Grima, MT; Hering, D; Karapanagiotidis, S; Kobayashi, D; Lambert, EA; Lambert, GW; Mariani, JA; Nestel, PJ; Phillips, SE; Sari, CI; Schlaich, MP; Straznicky, NE, 2015) |
| "Given that weight loss is challenging to achieve and maintain, we also consider evidence linking treatments for obesity-associated co-morbidities, including metformin, statins and non-steroidal anti-inflammatory drugs, with reduced breast and prostate cancer incidence and mortality." | ( Allott, EH; Hursting, SD, 2015) |
| "Weight loss is readily achievable but there is considerable challenge in maintaining that weight loss over the long term." | ( Liu, AY; Poppitt, SD; Silvestre, MP, 2015) |
| "Initial successful weight loss is often followed by weight regain after the dietary intervention." | ( Bouwman, FG; Camps, SG; Mariman, EC; Renes, J; Roumans, NJ; Westerterp, KR, 2016) |
| "Weight loss is the key determinant of diabetes remission one year after surgery." | ( Angrisani, L; Capaldo, B; Cotugno, M; Griffo, E; Lupoli, R; Nosso, G; Pacini, G; Riccardi, G; Saldalamacchia, G, 2016) |
| "Sex differences in weight loss are often seen despite using the same weight loss program." | ( Callister, R; Collins, CE; Morgan, PJ; Williams, RL; Wood, LG, 2016) |
| "Diet-induced weight loss is effective in models of both inherent and allergic obese asthma, and our examination of the fecal microbiome revealed that the obesogenic Firmicutes/Bacteroidetes ratio was normalized after diet-induced weight loss." | ( Aliyeva, MI; Ather, JL; Bates, JH; Chung, M; Daphtary, NA; Dixon, AE; Forgione, PM; Georgsdottir, A; Hoyt, LR; Irvin, CG; Poynter, ME; Randall, MJ; Russell, SR; Suratt, BT, 2016) |
| "Early satiety and weight loss are common after esophagectomy, but the pathophysiology of these phenomena remains poorly understood." | ( Docherty, NG; Doyle, SL; Eckhardt, HG; Elliott, JA; Guinan, EM; Ravi, N; Reynolds, JV; Roux, CWL, 2017) |
| "An aim of weight loss is to reduce the risk of type 2 diabetes (T2D) in obese subjects." | ( Astrup, A; Hager, J; Masoodi, M; Saris, WH; Valsesia, A, 2016) |
| "Weight loss is considered part of gastrointestinal dysfunction seen in patients affected by Parkinson's disease, along with gastroparesis and reduced bowel peristalsis." | ( Avolio, C; De Francesco, V; Lalla, A; Martino, T; Melchionda, D; Specchio, LM; Tonti, P, 2016) |
| "Weight loss is expected to improve glycaemic control in patients with diabetes or at high risk hereof." | ( Andersson, C; Caterson, ID; Finer, N; James, WPT; Kamil, S; Torp-Pedersen, C, 2017) |
| "Weight loss is a common symptom of Parkinson's disease and is associated with impaired quality of life." | ( Boyd, J; Li, R; Pérez, A; Ren, X; Wills, AM, 2017) |
| "Weight loss is due primarily to reduced energy intake and increased energy expenditure." | ( An, J; Fang, D; Gao, Y; Lu, T; Meng, X; Ruan, HB; Wang, L; Wang, W; Wang, X; Yang, C; Zhang, J, 2017) |
| "Weight loss is commonly recommended for gout, but the magnitude of the effect has not been evaluated in a systematic review." | ( Astrup, A; Bartels, EM; Bliddal, H; Carmona, L; Christensen, R; Gudbergsen, H; Henriksen, M; Knop, FK; Kristensen, LE; Nielsen, SM; Perez-Ruiz, F; Singh, JA; Taylor, WJ; Wæhrens, EE, 2017) |
| "Weight loss is an established strategy to improve metabolic risk, including dyslipidemia." | ( Brown, WA; Burton, PR; Doyle, L; Earnest, A; Laurie, C; le Roux, CW; O'Brien, PE; Ooi, GJ; Sikaris, K; Wentworth, JM, 2018) |
| "The maintenance of weight loss is a public health challenge, and as non-communicable diseases become more prevalent with increasing age, mid-older adults could benefit from programs which motivate weight loss maintenance." | ( Bauman, A; Grunseit, AC; Lawler, L; McGill, B; O'Hara, BJ; Osborne, D; Phongsavan, P, 2018) |
| "Weight loss is the mainstay of treatment in prediabetes, but therapies that improved endothelial function and vasodilation may not only prevent cardiovascular disease but also slow progression to diabetes mellitus." | ( Brown, NJ; Wang, TJ; Wasserman, DH, 2018) |
| "The weight loss is due to loss of appetite resulting in reduced energy intake, and we find it probable that this process is driven by exaggerated secretion of appetite-regulating gut hormones including, but probably not limited to, glucagon-like peptide-1 and peptide-YY." | ( Bojsen-Møller, KN; Dirksen, C; Holst, JJ; Jørgensen, NB; Madsbad, S; Martinussen, C; Svane, MS, 2018) |
| "Achieving weight loss is the cornerstone of the treatment of the metabolic consequences of obesity, in particular of glucose intolerance." | ( Bedossa, P; Corbeels, K; Gesquiere, I; Lannoo, M; Mathieu, C; Matthys, C; Mertens, A; Meulemans, A; Monteiro Carvalho Mori Cunha, JP; Overbergh, L; van der Ende, M; van der Merwe, S; Van der Schueren, B; Vangoitsenhoven, R, 2018) |
| "Weight loss is achievable with lifestyle intervention in those with heart failure and obesity and may result in improvements in New York Heart Association classification, quality of life and exercise capacity." | ( Logue, J; McDowell, K; Petrie, MC; Raihan, NA, 2018) |
| "Unexplained weight loss is a non-specific complaint with myriad potential etiologies." | ( Chua, W; Dan, YY; Goh, Y; Jagmohan, P; Lee, JK; Thian, YL, 2018) |
| "Weight loss is a strong prognostic factor in chronic heart failure (CHF); however, little is known about its effects in patients with mild CHF." | ( Asakura, M; Ishihara, M; Masuyama, T; Naito, Y; Okuhara, Y; Orihara, Y; Tsujino, T, 2019) |
| "Weight loss is associated with an improvement in QoL; and when matched for age and obesity, PCOS was not independently associated with reduced QoL or depression." | ( Atkin, S; Coady, A; Kahal, H; Kilpatrick, E; Rigby, A, 2019) |
| "The weight loss is less than expected from urinary glucose loss, however, likely because of an increase in food intake." | ( Hara, K; Hirota, Y; Kishi, M; Komada, H; Kuroki, Y; Matsuda, T; Miura, H; Ogawa, W; Ohara, T; Okada, Y; Otowa-Suematsu, N; Sakaguchi, K; So, A; Takeda, A; Tamori, Y; Yamada, T; Yokota, K, 2019) |
| "In conclusion, if weight loss is the primary goal of surgical intervention, significant volume reduction is required, and this most likely requires excising gastric tissue." | ( Alvarez, R; Evers, SS; Grant, B; Lewis, AG; Ridelman, E; Seeley, RJ; Shao, Y; Tong, C, 2020) |
| "Weight loss is common among IPF patients on antifibrotic therapy." | ( Culver, DA; Glennie, J; Li, M; Olman, MA; Perelas, A; Scheraga, RG; van Kerkhove, K, 2019) |
| "Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes." | ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020) |
| "Weight loss is traditionally viewed as straightforward counting of calories in and calories out, with little regard to the role of the adipocytes tasked with storing said calories." | ( Davis, W; Lawrence, N, 2020) |
| "Weight loss is almost universal early after congenital heart surgery and is associated with complex surgery and cumulative nil-per-oral duration." | ( Balachandran, R; Banerji, N; Kotayil, BP; Krishna Kumar, R; Sudhakar, A; Sunil, GS, 2020) |
| "Weight loss is key to treatment of older adults with obesity and type 2 diabetes, but also a risk for muscle mass loss." | ( Bongers, A; de Vogel-van den Bosch, J; Memelink, RG; Pasman, WJ; Tromp, W; Tump, A; van Ginkel, A; Verlaan, S; Weijs, PJM; Wopereis, S, 2020) |
| "Weight loss is critical for preventing and managing obesity-related diseases." | ( Astrup, A; Bartels, EM; Bartholdy, C; Bliddal, H; Boesen, M; Christensen, R; Danneskiold-Samsøe, B; Daugaard, CL; Ellegaard, K; Gudbergsen, H; Heitmann, BL; Henriksen, M; Knop, FK; Kristensen, LE; Nielsen, SM; Overgaard, A; Rasmussen, MU; Wæhrens, EE, 2021) |
| "Maintaining weight loss is extremely difficult due to the neuro-endocrine dysregulations that stimulate the body to return to the previous, increased, weight." | ( Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS, 2021) |
| "weight loss is commonly observed with ageing." | ( Fratiglioni, L; Guo, J; Johnell, K; Marseglia, A; Shang, Y; Welmer, AK; Xu, W, 2021) |
| "Weight regain after weight loss is a major problem in the treatment of persons with obesity." | ( Bandholm, T; Blond, MB; Bojsen-Møller, KN; Christensen, RM; Holst, JJ; Janus, C; Jensen, JB; Jensen, SBK; Juhl, CR; Lundgren, JR; Madsbad, S; Olsen, LM; Stallknecht, BM; Svane, MS; Torekov, SS, 2021) |
| "Weight loss is common in advanced gastric and gastroesophageal junction adenocarcinoma (G/GEA); however, the prognostic implications of weight loss during the first cycle (C1) of chemotherapy remain poorly characterized." | ( Abada, P; Chatterjee, A; Chaudhry, A; Klempner, SJ; Knoderer, H; Liepa, AM; Mansoor, W; Roeland, EJ; Wei, R, 2021) |
| "Body weight loss is frequently regarded as negatively related to outcomes in patients with malignancies." | ( Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF, 2022) |
| "Weight loss is an obvious management for this, but a major problem is that after weight loss, many people regain weight." | ( Doggrell, SA, 2022) |
| "Malnutrition and weight loss are commonly observed in patient with esophageal and esophagogastric junction (EGJ) cancers." | ( Hiranyatheb, P; Jiarpinitnun, C; Ngamphaiboon, N; Wiwitkeyoonwong, J, 2021) |
| "PFMT and weight loss are the most effective treatments for UI, but there is no evidence for other PFDs." | ( Bascur-Castillo, C; Carrasco-Portiño, M; Orellana-Gaete, L; Ruiz Cantero, MT; Valenzuela-Peters, R; Viveros-Allende, V, 2022) |
| "Anorexia and weight loss are common complications in the elderly, advanced cancer population." | ( Burger, A; Eladghm, N; Gamaleldin, A; Marie Gavioli, E; Vider, E, 2022) |
| "Weight loss is recommended for obese patients with cardiovascular risk; however, it remains questionable how hyperglycemia affects this process." | ( Birková, A; Błaszczyk, U; Čižmárová, B; Fiolka, R; Grzanka, A; Hubková, B; Kasperczyk, S; Mareková, M; Szlachta, B; Toborek, M; Wielkoszyński, T; Wylęgała, A; Zalejska-Fiolka, J, 2022) |
| "Weight loss is effective in reducing hyperfiltration in most, but not all patients." | ( Antonioli, L; Bellini, R; Masi, S; Moriconi, D; Nannipieri, M; Pellegrini, C; Rebelos, E; Taddei, S, 2022) |
| "Unintentional weight loss is defined as a more than 5% decrease in body weight within 1 year." | ( Can, B; Durmuş, NŞ; Tufan, A, 2022) |
| "Weight loss is recommended for improving glycemic control and reducing cardiovascular risk factors in persons with diabetes." | ( Johnson, KC; Khedkar, SV; Zhao, Q, 2022) |
| "Weight loss is important both to treat obesity and to prevent the development of complications." | ( Armentaro, G; Arturi, F; Cassano, V; Giofrè, F; Pelle, MC; Sciacqua, A; Zaffina, I, 2023) |
| "Moreover, rapid weight loss is associated with an increased incidence of postsurgical cholelithiasis." | ( Alamro, N; Almuqati, A; Azhar, W; Azhri, AS; Azzeh, F; Ghafouri, K; Qadhi, A, 2023) |
| "Weight loss is recognized as an adverse event during nintedanib treatment, and is a common complication exploitable as a prognostic indicator of IPF." | ( Amimoto, H; Hashimoto, R; Iwabayashi, M; Tomioka, H; Yokota, M, 2023) |
| "Diet-induced weight loss is associated with improved beta-cell function in people with type 2 diabetes (T2D) with remaining secretory capacity." | ( Almdal, TP; Bennetsen, SL; Brønd, JC; Christensen, R; Durrer, CG; Feineis, CS; Hartmann, B; Holst, JJ; Karstoft, K; Legaard, GE; Liebetrau, B; Lyngbæk, MPP; Nielsen, NS; Nystrup, U; Pedersen, BK; Ried-Larsen, M; Solomon, TPJ; Thomsen, K; Trinh, B; Van Hall, G; Østergaard, M, 2023) |
| "Poor weight loss is associated with lower circulating levels of glucagon-like peptide-1 (GLP-1)." | ( Adamo, M; Adeleke, MO; Batterham, RL; Brown, A; Carnemolla, A; Devalia, K; Elkalaawy, M; Fakih, N; Firman, C; Jassil, FC; Jenkinson, A; Magee, CG; Makahamadze, C; Makaronidis, J; Marvasti, P; Mok, J; Omar, RZ; Pucci, A, 2023) |
| "Exercise and weight loss are associated with a decreased risk of breast cancer recurrence in breast cancer survivors with overweight or obesity, which may be mediated through reduced leptin levels, increased adiponectin levels, and an elevated adiponectin to leptin (A:L) ratio." | ( Brown, JC; Gordon, BR; Lin, D; Sarwer, DB; Schmitz, KH; Sears, DD; Sturgeon, KM, 2023) |
| "Weight regain after weight loss is a major challenge in the treatment of obesity." | ( Chen, X; Feng, X; Guo, Q; Huang, Y; Lu, RB; Luo, XH; Sun, H; Wang, LW; Zhou, HY; Zhou, R, 2023) |
| "Weight loss is associated with a disproportionate reduction in energy expenditure, along with increases in hunger feelings and ghrelin concentrations." | ( Gower, BA; Hunter, GR; Martins, C; Rehfeld, JF; Roekenes, JA, 2023) |